CCN2 and pancreatic neoplasm: Indeed, while the CTGF antibody FG-3019 (pamrevlumab) is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (Sgalla et al., 2020) and locally-advanced unresectable pancreatic cancer (ClinicalTrials.gov Identifier: NCT03955146) and in Phase 2 clinical development for Duchenne muscular dystrophy (ClinicalTrials.gov Identifier: NCT02606136) and COVID-19 (ClinicalTrials.gov Identifier: NCT04432298), it has never been assayed as a cardioprotective drug after MI injury.